These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38087151)

  • 1. An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund.
    Trigg LA; Barnish MS; Hayward S; Shaw N; Crathorne L; Groves B; Spoors J; Strong T; Melendez-Torres GJ; Farmer C
    Pharmacoecon Open; 2024 Mar; 8(2):303-311. PubMed ID: 38087151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
    Morrell L; Wordsworth S; Schuh A; Middleton MR; Rees S; Barker RW
    BMC Health Serv Res; 2018 May; 18(1):393. PubMed ID: 29855313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
    Dunlop W; van Keep M; Elroy P; Perez ID; Ouwens MJNM; Sarbajna T; Zhang Y; Greystoke A
    Pharmacoecon Open; 2022 Mar; 6(2):241-252. PubMed ID: 34532842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Don't Think Twice, It's All Right": Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England.
    Kang J; Cairns J
    Pharmacoecon Open; 2023 Jan; 7(1):77-91. PubMed ID: 36123583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.
    Aggarwal A; Fojo T; Chamberlain C; Davis C; Sullivan R
    Ann Oncol; 2017 Aug; 28(8):1738-1750. PubMed ID: 28453615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cancer Drugs Fund in Practice and Under the New Framework.
    Sabry-Grant C; Malottki K; Diamantopoulos A
    Pharmacoeconomics; 2019 Jul; 37(7):953-962. PubMed ID: 30941698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs.
    Shengnan D; Zixuan L; Na Z; Weikai Z; Yuanyuan Y; Jiasu L; Ni Y
    Front Public Health; 2022; 10():964040. PubMed ID: 36187695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
    Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process.
    Walton MJ; O'Connor J; Carroll C; Claxton L; Hodgson R
    Pharmacoecon Open; 2019 Sep; 3(3):403-410. PubMed ID: 30617953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Walton M; Sharif S; Simmonds M; Claxton L; Hodgson R
    Pharmacoeconomics; 2019 Oct; 37(10):1209-1217. PubMed ID: 30982165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
    Facey KM; Espin J; Kent E; Link A; Nicod E; O'Leary A; Xoxi E; van de Vijver I; Zaremba A; Benisheva T; Vagoras A; Upadhyaya S
    Pharmacoeconomics; 2021 Sep; 39(9):1021-1044. PubMed ID: 34231135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Otten T; Riemsma R; Wijnen B; Armstrong N; Stirk L; Gordon C; Ramaekers B; Kleijnen J; Joore M; Grimm S
    Pharmacoeconomics; 2022 Sep; 40(9):851-861. PubMed ID: 35802295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund.
    Leigh S; Granby P
    Value Health; 2016; 19(5):567-76. PubMed ID: 27565274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Carroll C; Stevens J; Simpson E; Thokala P; Wong R; Wright J; Auer R
    Pharmacoeconomics; 2019 Jan; 37(1):7-18. PubMed ID: 29951793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Did It Matter That the Cancer Drugs Fund Was Not NICE? A Retrospective Review.
    Dixon P; Chamberlain C; Hollingworth W
    Value Health; 2016; 19(6):879-884. PubMed ID: 27712717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.